Arbutus Intangible Assets vs Long Term Debt Analysis
ABUS Stock | USD 3.42 0.09 2.56% |
Arbutus Biopharma financial indicator trend analysis is way more than just evaluating Arbutus Biopharma Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arbutus Biopharma Corp is a good investment. Please check the relationship between Arbutus Biopharma Intangible Assets and its Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Intangible Assets vs Long Term Debt
Intangible Assets vs Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arbutus Biopharma Corp Intangible Assets account and Long Term Debt. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Arbutus Biopharma's Intangible Assets and Long Term Debt is -0.04. Overlapping area represents the amount of variation of Intangible Assets that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Arbutus Biopharma Corp, assuming nothing else is changed. The correlation between historical values of Arbutus Biopharma's Intangible Assets and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Intangible Assets of Arbutus Biopharma Corp are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Intangible Assets i.e., Arbutus Biopharma's Intangible Assets and Long Term Debt go up and down completely randomly.
Correlation Coefficient | -0.04 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Long Term Debt
Long-term debt is a debt that Arbutus Biopharma Corp has held for over one year. Long-term debt appears on Arbutus Biopharma Corp balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Arbutus Biopharma Corp balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Most indicators from Arbutus Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arbutus Biopharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. At this time, Arbutus Biopharma's Issuance Of Capital Stock is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 2.32 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.
Arbutus Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Arbutus Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arbutus Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 105.5M | 137.1M | 204.5M | 195.4M | 144.4M | 124.4M | |
Other Current Liab | 253K | 5.8M | 7.3M | 20.5M | 9.9M | 10.4M | |
Total Current Liabilities | 7.8M | 9.5M | 11.2M | 32.9M | 22.5M | 23.6M | |
Total Stockholder Equity | 72.7M | 102.0M | 169.4M | 136.9M | 106.0M | 93.5M | |
Property Plant And Equipment Net | 11.4M | 9.3M | 8.1M | 6.8M | 6.1M | 4.8M | |
Net Debt | (28.4M) | (49.3M) | (106.7M) | (28.6M) | (17.6M) | (18.4M) | |
Retained Earnings | (970.1M) | (1.0B) | (1.1B) | (1.2B) | (1.3B) | (1.2B) | |
Cash | 31.8M | 52.3M | 109.3M | 30.8M | 26.3M | 39.9M | |
Non Current Assets Total | 11.7M | 9.4M | 43.8M | 44.3M | 12.4M | 11.8M | |
Non Currrent Assets Other | 293K | 44K | 61K | 103K | 92.7K | 88.1K | |
Cash And Short Term Investments | 90.8M | 123.3M | 155.3M | 146.9M | 126.0M | 73.6M | |
Net Receivables | 1.2M | 1.3M | 899K | 1.4M | 1.8M | 1.3M | |
Common Stock Total Equity | 898.5M | 985.9M | 1.3B | 1.3B | 1.5B | 1.6B | |
Common Stock Shares Outstanding | 57.1M | 75.8M | 106.2M | 150.9M | 166.0M | 174.3M | |
Short Term Investments | 59.0M | 71.0M | 46.0M | 116.1M | 99.7M | 104.7M | |
Liabilities And Stockholders Equity | 105.5M | 137.1M | 204.5M | 195.4M | 144.4M | 124.4M | |
Non Current Liabilities Total | 25.0M | 25.6M | 23.8M | 25.7M | 15.9M | 25.0M | |
Other Current Assets | 1.8M | 6.2M | 8.9M | 2.9M | 3.6M | 3.8M | |
Other Stockholder Equity | 55.2M | 60.8M | 65.5M | 72.4M | 81.3M | 85.3M | |
Total Liab | 32.8M | 35.1M | 35.0M | 58.6M | 38.4M | 31.0M | |
Property Plant And Equipment Gross | 11.4M | 9.3M | 8.1M | 6.8M | 18.0M | 18.9M | |
Total Current Assets | 93.8M | 127.7M | 160.7M | 151.1M | 132.0M | 76.6M | |
Common Stock | 898.5M | 985.9M | 1.3B | 1.3B | 1.3B | 1.4B | |
Other Liab | 21.9M | 23.0M | 21.6M | 23.9M | 27.5M | 18.6M | |
Net Tangible Assets | (64.5M) | (47.4M) | 169.4M | 136.9M | 157.4M | 165.2M | |
Accounts Payable | 2.4M | 3.0M | 3.2M | 3.5M | 3.2M | 2.5M | |
Retained Earnings Total Equity | (970.1M) | (1.0B) | (1.1B) | (1.2B) | (1.1B) | (1.0B) | |
Preferred Stock Total Equity | 49.8M | 126.1M | 137.3M | 149.4M | 171.8M | 180.4M | |
Accumulated Other Comprehensive Income | (48.2M) | (48.2M) | (48.3M) | (50.5M) | (48.4M) | (46.0M) | |
Property Plant Equipment | 8.7M | 6.9M | 6.0M | 5.1M | 5.8M | 4.5M | |
Capital Surpluse | 55.2M | 60.8M | 65.5M | 72.4M | 83.3M | 53.5M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.